The pharmaceutical giant is embroiled in a legal dispute with rival Eli Lilly over weight-loss dr-g advertising. Simultaneously, a new safety warning regarding optic nerve stroke has been added to the prescribing information for its semaglutide-based dr-gs. These issues compound recent disappointing trial results and significant workforce reductions. The company is also facing regulatory scrutiny at a manufacturing facility in Indiana. Despite these headwinds, Novo Nordisk has partnered with Amazon Web Services to enhance its digital capabilities.
https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/novo-nordisk-s-multi-front-storm-legal-action-mass-layoffs-and-a-stock/69963154